T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Constellation Energy
CEG
$98.7B
| $1.04B | 0.11% |
2,946,545
-1,184,250
| -29% | -$430M |
|
152
Northrop Grumman
NOC
$82B
| $1.04B | 0.11% |
1,817,977
-487,629
| -21% | -$283M |
|
153
W.W. Grainger
GWW
$61.5B
| $1.04B | 0.11% |
1,027,286
+389,589
| +61% | +$378M |
|
154
Vertex Pharmaceuticals
VRTX
$133B
| $1.03B | 0.11% |
2,278,958
-764,847
| -25% | -$330M |
|
155
Williams Companies
WMB
$90.1B
| $1.03B | 0.11% |
17,140,207
-441,395
| -3% | -$26.7M |
|
156
Ball Corp
BALL
$16.4B
| $1B | 0.11% |
18,886,681
+999,690
| +6% | +$49.2M |
|
157
American Tower
AMT
$79.4B
| $995M | 0.11% |
5,666,920
-530,095
| -9% | -$96.5M |
|
158
TransDigm Group
TDG
$68.3B
| $993M | 0.11% |
746,559
-2,154
| -0.3% | -$2.82M |
|
159
Viatris
VTRS
$18.5B
| $985M | 0.11% |
79,079,870
-4,984,896
| -6% | -$53.8M |
|
160
Range Resources
RRC
$9.39B
| $975M | 0.11% |
27,660,494
+326,748
| +1% | +$12.2M |
|
161
Ares Management
ARES
$32.1B
| $968M | 0.1% |
5,987,733
-1,582,336
| -21% | -$247M |
|
162
Equity Lifestyle Properties
ELS
$12.4B
| $967M | 0.1% |
15,948,613
+11,999,874
| +304% | +$742M |
|
163
Ciena
CIEN
$61.2B
| $948M | 0.1% |
4,051,625
+1,404,132
| +53% | +$272M |
|
164
Capital One
COF
$136B
| $921M | 0.1% |
3,800,000
-78,324
| -2% | -$17.4M |
|
165
Equifax
EFX
$21.2B
| $914M | 0.1% |
4,212,836
-1,741,584
| -29% | -$381M |
|
166
Essex Property Trust
ESS
$18.1B
| $879M | 0.09% |
3,358,320
-313,561
| -9% | -$81.2M |
|
167
Moody's
MCO
$82.8B
| $877M | 0.09% |
1,716,304
+726,971
| +73% | +$355M |
|
168
Middleby
MIDD
$5.38B
| $858M | 0.09% |
5,772,249
+1,902,957
| +49% | +$250M |
|
169
Sempra
SRE
$56.2B
| $847M | 0.09% |
9,588,316
-559,140
| -6% | -$50.9M |
|
170
Hartford Financial Services
HIG
$37.7B
| $839M | 0.09% |
6,089,609
-2,475,912
| -29% | -$327M |
|
171
Revvity
RVTY
$13.2B
| $833M | 0.09% |
8,606,637
+434,570
| +5% | +$41.7M |
|
172
Becton Dickinson
BDX
$50B
| $830M | 0.09% |
4,279,200
-343,337
| -7% | -$65.3M |
|
173
Equitable Holdings
EQH
$14.1B
| $822M | 0.09% |
17,258,124
+1,132,861
| +7% | +$53.7M |
|
174
Teradyne
TER
$63B
| $814M | 0.09% |
4,203,546
+659,273
| +19% | +$113M |
|
175
Norfolk Southern
NSC
$75.3B
| $802M | 0.09% |
2,778,515
-1,061,631
| -28% | -$307M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.